Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000950170-24-032989

Chief Executive Officer sold 20,000 shares at an average $72.48 ($1,449,628)

  • Chief Executive Officer acquired 20,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2024-03-15 Option exercise 10b5-1 +20,000 $19.12 $382,400 228,122 D
Kulkarni Samarth Chief Executive Officer 2024-03-15 Sale 10b5-1 −10,613 $71.97 $763,810 217,509 D
Kulkarni Samarth Chief Executive Officer 2024-03-15 Sale 10b5-1 −9,387 $73.06 $685,818 208,122 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2024-03-15 Option exercise · Stock Option (Right to Buy) 10b5-1 −20,000 19,582 D
Open-market sales · 20,000 sh · avg $72.48 · $1,449,628
Loading xslF345X05/ownership.xml…